HeiLongJiang ZBD Pharmaceutical Co.,Ltd.
- Country
- Ownership
- -
- Established
- 1996-10-28
- Employees
- 465
- Market Cap
- -
- Website
- www.zbdzy.com
- Introduction
The company is a large company listed on the Shanghai Stock Exchange dedicated to providing high-quality products and services for human health. As one of the top 100 enterprises in China's pharmaceutical industry, the company focuses on the development direction of innovation and creativity, high quality, and high technology. Its business covers four major sectors: scientific research and development, pharmaceutical industry, traditional Chinese medicine industry, and financial investment. It is one of the most innovative pharmaceutical enterprises in China's pharmaceutical industry. The company's main business is pharmaceutical R&D, production and sales. Main products: 3 protected varieties of traditional Chinese medicine: Cuproton Capsules, Compound Qinlan Oral Liquid, and Pediatric Hot Quick Clear Syrup, as well as 4 exclusive varieties of Compound Qalan Oral Liquid, Lingqi Plus Oral Liquid, and Compound Baitouweng Capsules. The company won the “Leading Power · High-Quality Development of Chinese Medicine” Achievement Enterprise and Achievement Brand Award; it was also shortlisted on the Ministry of Industry and Information Technology's 2022 Green Manufacturing List and on the “National Green Factory List”. The list of China's top 100 pharmaceutical industry series, ranked 26th in the “2022 Chinese Traditional Chinese Medicine Companies”; ranked 21st in the “2022 TOP30 Listed Chinese Medicine Companies”, 22nd in the “2022 Top 100 Chinese Medicine Companies”, 23rd in the “2023 China Proprietary Chinese Medicine Industry TOP100”, 29th in the “2023 China Pharmaceutical R&D Strength Ranking”, and 48th in the “2022 Top 100 Chinese Pharmaceutical Manufacturing Companies”. With high quality development results and representative product - injectable hemostone, it won the title of “Excellent Brand Enterprise of Chinese Ethnic Medicine for the Year 2022 - 2023”.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
73
Drug Approvals
Bromhexine Hydrochloride Injection
- Product Name
- 盐酸溴己新注射液
- Approval Number
- 国药准字H20244392
- Approval Date
- Jul 9, 2024
Esomeprazole Magnesium Enteric-coated Tablets
- Product Name
- 艾司奥美拉唑镁肠溶片
- Approval Number
- 国药准字H20243685
- Approval Date
- May 15, 2024
Levetiracetam Concentrated Solution for Injection
- Product Name
- 左乙拉西坦注射用浓溶液
- Approval Number
- 国药准字H20243584
- Approval Date
- Apr 24, 2024
Tofacitinib Citrate Tablets
- Product Name
- 枸橼酸托法替布片
- Approval Number
- 国药准字H20243171
- Approval Date
- Feb 6, 2024
Levetiracetam Oral Solution
- Product Name
- 左乙拉西坦口服溶液
- Approval Number
- 国药准字H20234346
- Approval Date
- Dec 18, 2023
Ambroxol Hydrochloride Oral Solution
- Product Name
- 盐酸氨溴索口服溶液
- Approval Number
- 国药准字H20233460
- Approval Date
- Jul 19, 2023
Sterile Water for Injection
- Product Name
- 灭菌注射用水
- Approval Number
- 国药准字H23022152
- Approval Date
- Nov 10, 2021
Sterile Water for Injection
- Product Name
- 灭菌注射用水
- Approval Number
- 国药准字H23022154
- Approval Date
- Nov 10, 2021
Sterile Water for Injection
- Product Name
- 灭菌注射用水
- Approval Number
- 国药准字H23022151
- Approval Date
- Nov 10, 2021
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next